Prostate-specific antigen testing across the spectrum of prostate cancer

Biomarkers in Medicine

Volumn 5, Issue 4, 2011, Pages 515-526

  Haythorn, Mark R ^a   Ablin, Richard J ^a,b  

^a Robert Benjamin Ablin Foundation for Cancer Research   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

disease monitoring; prostate cancer; prostate specific antigen; PSA; screening

Indexed keywords

DOCETAXEL; ESTRAMUSTINE; PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; DIGITAL RECTAL EXAMINATION; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GENE OVEREXPRESSION; GLEASON SCORE; HUMAN; MALE; MARKER GENE; OVERALL SURVIVAL; PCA3 GENE; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TUMOR BIOPSY;

GOVERNMENT REGULATION; HUMANS; MALE; MASS SCREENING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 79958794101     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.11.53     Document Type: Review

References (54)

1. Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specifc antigen level < or = 4.0 ng per milliliter. N. Engl. J. Med. 350(22), 2239-2246 (2004).
2. Ablin RJ, Whyard TC. Immunobiological Implications of Select Bioactive Molecules in the Prostate with a Known and Unknown Target. In: The Prostate as an Endocrine Gland. Farnsworth WE, Ablin RJ (Eds.). CRC Press, Inc., Boca Raton, 149 (1990).
3. Boyle P. Screening for prostate cancer: have you had your cholesterol measured? BJU Int. 92(3), 191-199 (2003). (Pubitemid 36966576)
4. Ablin RJ, Soanes WA, Bronson P et al. Precipitating antigens of the normal human prostate. J. Reprod. Fertil. 22(3), 573-574 (1970).
5. Ablin RJ, Bronson P, Soanes WA et al. Tissue-and species-specifc antigens of normal human prostatic tissue. J. Immunol. 104(6), 1329-1339 (1970).
6. Ablin RJ. Immunologic studies of normal, benign, and malignant human prostatic tissue. Cancer 29(6), 1570-1574 (1972).
7. Moffat LE. Pragmatism and PSA. BJU Int. 92(4), 340-341 (2003). (Pubitemid 37100502)
8. Papsidero LD, Wang MC, Valenzuela LA et al. A prostate antigen in sera of prostatic cancer patients. Cancer Res. 40(7), 2428-2432 (1980). (Pubitemid 10082262)
9. Cragun JM. Screening for ovarian cancer. Cancer Control 18(1), 16-21 (2011).
10. Wilson JMG, Jungner G. Principles and practice of screening for disease. Public Health Paper Number 34. Geneva, WHO (1968).
11. Sakr WA, Grignon DJ, Haas GP et al. Age and racial distribution of prostatic intraepithelial neoplasia. Eur. Urol. 30(2), 138-144 (1996). (Pubitemid 26285528)
12. Sölétormos G, Semjonow A, Sibley PE et al. Biological variation of total prostate-specifc antigen: a survey of published estimates and consequences for clinical practice. Clin Chem. 51(8), 1342-1351 (2005). (Pubitemid 41060864)
13. Link RE, Shariate SF, Nguyen CV et al. Variation in prostate specifc antigen results from 2 different assay platforms: clinical impact on 2,304 patients undergoing prostate cancer screening. Clin. Urol. 171(6, Part 1), 2234-2238 (2004). (Pubitemid 38625442)
14. Kobayashi M, Kurokawa S, Tokue A. Intraindividual variation in total and percent free prostate-specifc antigen levels in prostate cancer suspects. Urol. Int. 74(3), 198-202 (2005). (Pubitemid 41201528)
15. Thompson IM, Ankerst DP, Chi C et al. Operating characteristics of prostate-specifc antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294(1), 66-70 (2005). (Pubitemid 41002840)
16. Shao YH, Albertsen PC, Roberts CB et al. Risk profles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specifc antigen level below 4.0 ng/ml. Arch. Intern. Med. 170(14), 1256-1261 (2010).
17. Parker C, Muston D, Melia J et al. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br. J. Cancer 94(10), 1361-1368 (2006). (Pubitemid 43772267)
18. Lu-Yao G, Albertsen PC, Stanford JL et al. Screening, treatment, and prostate cancer mortality in the Seattle area and Connecticut: ffteen-year follow-up. J. Gen. Intern. Med. 23(11), 1809-1814 (2008).
19. Andriole GL, Crawford ED, Grubb RL 3rd et al. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360(13), 1310-1319 (2009).
20. Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360(13), 1320-1328 (2009).
21. Loeb S, Vonesh EF, Metter EJ et al. What is the true number needed to screen and treat to save a life with prostate-specifc antigen testing? J. Clin. Oncol. 29(4), 464-467 (2011).
22. Hugosson J, Carlsson S, Aus G et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 11(8), 725-732 (2010).
23. Carlsson S, Aus G, Bergdahl S et al. The excess burden of side-effects from treatment in men allocated to screening for prostate cancer. The Goteborg randomised population-based prostate cancer screening trial. Eur. J. Cancer 47(4), 545-553 (2011).
24. Kelly WK, Scher HI, Mazumdar M et al. Prostate-specifc antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 11(4), 607-615 (1993). (Pubitemid 23105667)
25. Verbel DA, Heller G, Kelly WK et al. Quantifying the amount of variation in survival explained by prostate-specifc antigen. Clin. Cancer Res. 8(8), 2576-2579 (2002). (Pubitemid 34856342)
26. Denmeade SR, Sokoll LJ, Dalrymple S et al. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specifc differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate 54(4), 249-257 (2003). (Pubitemid 36228161)
27. Dixon SC, Knopf KB, Figg WD. The control of prostate-specifc antigen expression and gene regulation by pharmacological agents. Pharmacol. Rev. 53(1), 73-91 (2001). (Pubitemid 32173108)
28. Seckin B, Anthony CT, Murphy B et al. Can prostate-specifc antigen be used as a valid end point to determine the effcacy of chemotherapy for advanced prostate cancer? World J. Urol. 14(Suppl. 1), S26-S29 (1996).
29. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351(15), 1502-1512 (2004). (Pubitemid 39315317)
30. Armstrong AJ, Garrett-Mayer E, Ou Yang YC et al. Prostate-specifc antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 25(25), 3965-3970 (2007). (Pubitemid 47477275)
31. Angie MA. Accurate use of prostate-specifc antigen in determining risk of prostate cancer. J. Nurse Pract. 6(3), 177-184 (2010).
32. Ablin RJ. PSA assays. Lancet Oncol. 1(1), 13 (2000).
33. Ablin RJ. A retrospective and prospective overview of prostate-specifc antigen. J. Cancer Res. Clin. Oncol. 123(11-12), 583-594 (1997). (Pubitemid 28035496)
34. Leinonen J, Zhang WM, Stenman UH. Complex formation between PSA isoenzymes and protease inhibitors. J. Urol. 155(3), 1099-1103 (1996). (Pubitemid 26052723)
35. Mikolajczyk SD, Marker KM, Millar LS et al. A truncated precursor form of prostate-specifc antigen is a more specifc serum marker of prostate cancer. Cancer Res. 61(18), 6958-6963 (2001). (Pubitemid 32896525)
36. Catalona WJ, Bartsch G, Rittenhouse HG et al. Serum pro prostate specifc antigen improves cancer detection compared to free and complexed prostate specifc antigen in men with prostate specifc antigen 2 to 4 ng/ml. J. Urol. 170(6 Pt 1), 2181-2185 (2003). (Pubitemid 37413952)
37. Sokoll LJ, Sanda MG, Feng Z et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol. Biomarkers Prev. 19(5), 1193-1200 (2010).
38. Herwig R, Mitteregger D, Djavan B et al. Detecting prostate cancer by intracellular macrophage prostate-specifc antigen (PSA): a more specifc and sensitive marker than conventional serum total PSA. Eur. J.Clin. Invest. 38(6), 430-7 (2008). (Pubitemid 351712925)
39. Peracaula R, Tabares G, Royle L et al. Altered glycosylation pattern allows the distinction between prostate-specifc antigen (PSA) from normal and tumor origins. Glycobiology 13(6), 457-470 (2003). (Pubitemid 36665420)
40. Dwek MV, Jenks A, Leathem AJ. A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate specifc antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia. Clin. Chim. Acta 411(23-24), 1935-1939 (2010).
41. Cramer SD, Chang BL, Rao A et al. Association between genetic polymorphisms in the prostate-specifc antigen gene promoter and serum prostate-specifc antigen levels. J. Natl. Cancer Inst. 95(14), 1044-1053 (2003). (Pubitemid 36950108)
42. Gudmundsson J, Besenbacher S, Sulem P et al. Genetic correction of PSA values using sequence variants associated with PSA levels. Sci. Transl. Med. 2(62), 62-92 (2010).
43. Ding Z, Wu CJ, Chu GC et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 470(7333), 269-273 (2011).
44. Brussemakers MJ, van Bokhoven A, Verhaegh GW et al. DD3: a new prostate-specifc gene, highly over expressed in prostate cancer. Cancer Res. 59, 5975-9 (1999). (Pubitemid 30004960)
45. Dudderidge TJ, Kelly JD, Wollenschlaeger A et al. Diagnosis of prostate cancer by detection of minichromosome maintenance 5 protein in urine sediments. Br. J. Cancer 103(5), 701-707 (2010).
46. Cornu JN, Cancel-Tassin G, Ondet V et al. Olfactory detection of prostate cancer by dogs sniffng urine: a step forward in early diagnosis. Eur. Urol. 59(2), 197-201 (2011).
47. Shariat SF, Karakiewicz PI, Suardi N, Kattan MW. Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature. Clin. Cancer Res. 14 (14), 4400-4407 (2008).
48. Draisma G, Etzioni R, Tsodikov A et al. Lead time and overdiagnosis in prostate-specifc antigen screening: importance of methods and context. J. Natl. Cancer Inst. 101(6), 374-383 (2009).
49. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specifcity with free PSA measurements. JAMA 277(18), 1452-1455 (1997). (Pubitemid 27208887)
50. Welch HG, Schwartz LM, Woloshin S. Prostate-specifc antigen levels in the United States: implications of various defnitions for abnormal. J. Natl. Cancer Inst. 97(15), 1132-1137 (2005). (Pubitemid 41511212)
51. Barry MJ, Mulley AJ Jr. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important? J. Natl. Cancer Inst. 101(6), 362-363 (2009).
52. Allam CK, Bostwick DG, Hayes JA et al. Interobserver variability in the diagnosis of high-grade prostatic intraepithelial neoplasia and adenocarcinoma. Mod. Pathol. 9(7), 742-751 (1996). (Pubitemid 26246582)
53. Klotz LH: PSAdynia and other PSA-related syndromes: a new epidemic-a case history and taxonomy. Urology 50(6), 831-832 (1997).
54. Tannock IF. Eradication of a disease: how we cured symptomless prostate cancer. Lancet 359(9314), 1341-1342 (2002). (Pubitemid 34310645)